The charts of the producer of medical technology show promise but could be derailed by weakness in the broader markets.
The charts for this drug developer are starting to take shape.
Traders have been shifting from aggressive selling to aggressive buying.
The stock is ready to make a recovery rally.
Let's check the charts on this biotechnology stock and see if it still has a prayer.
The stock of the life sciences company has found buying interest at a key support level.
BDX gets an upgrade, but are the charts healthy enough to recommend?
The shares of the healthcare giant have been in a long-term uptrend but could break that trend in the weeks ahead.
These recently downgraded names are displaying both quantitative and technical deterioration.
Aggressive traders of the medical device maker's stock could probe the long side on weakness, such as it is seeing after posting fiscal fourth-quarter results.